Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
Aandelen, abnormal, Aktiengesellschaft, Annex, ARB, attempt, belief, Biomedical, Biosafety, BioSprint, bioterrorism, Bloodbourne, Boerse, bond, broader, broadest, Chester, Circle, Clarification, clearance, composed, concede, Connecticut, consecutive, contingency, contingent, coupon, Creation, crime, criterion, cRNA, curtail, deceased, default, depletion, DHL, diligence, Displacement, distributor, downturn, expenditure, FIN, Fisher, forward, Foundation, fractionation, fragmentation, GMO, great, Haven, Hazard, idle, Indenture, interrupted, intrinsic, inventor, IvDD, Karobathstudied, MDA, MDxDSP, membership, milestone, MSI, multiplied, multiplying, NYSE, OBI, OSHA, overcoming, Oversight, paragraph, partly, phone, Preferente, proteomic, QGEN, Qproteome, RCAT, realign, realigned, realignment, reappointed, reassessment, refinance, refocused, regime, reliance, repaid, repay, repurchase, rest, retail, revaluation, Rolling, scarce, Schatzjoined, smallest, SPAQ, spoilage, stand, sustain, threat, TMO, travel, Trustee, unanimity, unsubordinated, violation, vulnerable, warrant, WGA
Removed:
activated, actively, adsorb, affiliated, Alameda, alliance, ambion, America, analyzed, answer, antidilutive, applicability, arm, arrayable, assay, assignment, auditing, automatable, automate, bacterial, BD, begin, bind, biopharmaceutical, blend, blueprint, Boom, borrow, Borse, break, breakthrough, broken, buffer, bulk, bundle, bundled, capability, capable, capitalization, capture, CARDION, carryforward, carryover, cationic, ceased, cellular, cellulose, cerevisiae, Chain, chelate, chelating, CHF, choose, chosen, chromatography, circular, clearing, Cleavable, cleaving, clinically, cm, coated, coli, collected, collecting, column, combated, combine, combined, combining, commenced, commercialize, comparison, comprise, consortium, consultative, consuming, contact, contaminating, convenient, convey, copied, covering, CpG, CRM, crude, culture, cultured, cured, cycler, degradation, degraded, dendrimer, design, destroy, detergent, directional, discussion, disrupt, disseminating, diversify, donated, drawn, DSM, dynamic, easier, easily, economical, edge, edition, effectene, Ehrlich, elution, emphasize, employing, Empore, encoded, encompassing, endofree, endotoxin, enhanced, enhancement, enhancing, enzymatic, EPICEPT, eventually, exchanged, excluding, exponentially, extension, extremely, falciparum, faster, fastest, feedback, filtered, filtration, Fine, flexible, fluorescence, format, formation, formulated, formulation, fragile, frequently, fueled, GeneMedicine, govern, Green, harbor, hardware, harvested, Haserjian, HCV, HiSpeed, Histidine, historic, hormone, HotStarTaq, HS, hundred, hybrid, hybridization, ideal, immunization, immunoassay, improvement, inclusion, Indemnity, induce, induced, induction, inexpensive, influenza, initiated, initiative, insect, insertion, insoluble, insulin, intact, integrity, interaction, interferon, involving, Iowa, isolate, isolated, Jersey, labeling, larger, LCx, leveraged, LIBOR, ligand, linear, link, lipid, living, longmer, lysate, maintaining, mammalian, man, marginal, Masscode, massive, mechanically, melanogaster, membrane, metal, microinjection, miniprep, modifying, moving, mRNA, mutation, Mycobacterium, NTA, nucleotide, OEM, oligonucleotide, Oligotex, Omniscript, OneStep, open, optimization, optimize, optimized, Orchid, Organon, overhead, Overview, Pall, pAlliance, patented, Paul, penetrate, PerkinElmer, pertaining, phase, piece, plasma, Plasmodium, platform, PolyFect, polymerase, pooling, poor, popular, powerful, prepare, prerequisite, preservation, prevention, priced, primer, probe, procedure, productivity, profiling, prominently, promote, promoting, protected, protective, pure, purifying, QIAEX, QIAfilter, QIAprecipitator, QIAprep, QIAquick, QIAwell, quantification, RADIOMETER, RapidPlate, Rapigene, rat, realization, Realty, recombination, recommendation, recovering, recurring, Reform, regulating, removal, renamed, reproducibility, reproduction, reputation, resin, resonance, restricted, reversed, revolutionary, Richard, RLS, RNAlater, robotic, room, routine, RT, safe, safely, scattering, screening, selectively, SensiChip, Sensiscript, Sequenom, serum, shift, Sigma, signal, situated, sizeable, skill, smaller, SNP, soluble, Spectrometry, spread, stabilize, stabilizing, Stolberg, stored, structural, studied, Sugarman, suitable, SuperFect, surface, SYBR, synergistic, synergy, tag, tagged, tagging, tailored, targeted, technique, Teknika, temperature, template, terminated, thousand, tightly, tip, today, Tokyo, toxic, toxicology, trace, tracking, transcribed, transcribing, transcriptase, transfecting, TransMessenger, transported, TruPrepTM, TurboFilter, UA, ultrapurity, understand, understanding, uniquely, unparalleled, unstable, unsurpassed, vaccine, vacuum, validation, varying, vector, VGI, Visible, warehouse, washed, washing, Wave, workstation, yeast
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.1 Credit Contract for a Club Deal Between Qiagen & Deutsche Bank
- 2.2 Declaration by Qiagen N.V. to Deutsche Bank
- 2.3 Indenture Between Qiagen Finance S.a., Qiagen N.V. and Deutsche Bank
- 2.4 Agreement In Connection with the Delivery of Ordinary Shares
- 4.14 Letter Between Qiagen and DR. Joachim Schorr, Dated March 24, 2003
- 4.15 Letter Between Qiagen and DR. Joachim Schorr, Dated October 9, 2003
- 4.17 Letter Between Qiagen and Bernd Uder, Dated October 9,2003
- 4.18 Letter Between Qiagen and Bernd Uder Clarification, Dated October 9, 2003
- 4.19 Employment Agreement by and Between Qiagen and Roland Sackers, Dated 01/01/04
- 4.20 Employment Agreement by and Between Qiagen and Roland Sackers, Dated 01/05/04
- 4.21 Change of Control Agreement Between Qiagen and Roland Sackers, As of 09/30/03
- 4.22 Empolyment Agreement by and Between Qiagen N.V.& Roland Sackers, Dated 08/05/04
- 4.23 Consultancy Agreement Between Qiagen and DR. Metin Colpan, Dated 12/04/03
- 4.24 Letter Between Qiagen and Peer Schatz, Dated 10/09/03
- 8.1 List of Subsidiaries
- 12.1 Certifications Under Section 302; Peer Schatz, CEO
- 12.2 Certifications Under 302; Roland Sackers, CFO
- 13.1 Certifications Under Section 906; Peer Schatz, CEO and Roland Sackers, CFO
- 15.1 Consent of Ernst & Young LLP
QGEN similar filings
Filing view
External links
Exhibit 4.17
Dear Mr. Uder,
In addition to your employment contract with our Company dated March 1, 2001, we hereby agree as follows:
1. | In the event of a “Change of Control” you will receive compensation. A “Change of Control” is defined as: |
• | As used herein, a “Change in Control” shall be deemed to have occurred if (i) there is a sale or transfer of all or substantially all of the assets of the Company in one or a series of translations; or (ii) there is a merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation. |
2. | The compensation is calculated as follows: |
((13 x the then current monthly salary) + bonus) x 2 = compensation
• | The monthly salary is the agreed gross salary as per the employment contract in the month in which the Change of Control occurs. |
• | The bonus is the gross bonus and other variable cash components that were agreed for the year in which the Change of Control occurs. |
• | Other compensation components (e.g. company car) are not considered for the calculation of the compensation. |
• | The treatment of granted stock options is agreed on in a separate document. |
3. | The compensation is a gross sum which is subject to tax and other standard deductions. |
4. | The compensation is to be paid within 3 months after the Change of Control. |
5. | This agreement is valid for all changes of control pursuant to article 1 of this agreement and which occurs on or before Oct. 10, 2007. |
QIAGEN GmbH
Managing Director
I agree with the above provisions:
/s/ Bernd Uder | , | dated October 9, 2003 | ||
Bernd Uder | ||||
Employee |